
Innovative phage-based solution targeting Porphyromonas gingivalis, the oral pathogen linked to periodontal disease, using CRISPR-deficient mutants for precise bacteriophage isolation. This approach aims to reduce pathog...
Stella Maris Therapeutics is developing a bacteriophage-based nebulizer targeting common upper respiratory pathogens. This targeted, non-antibiotic therapy aims to reduce pathogen burden while preserving the microbiome, ...
Utilizing C. elegans models expressing human proteins, Stella Maris Therapeutics investigates gut microbial communities' impact on neurodegenerative diseases, aiming to develop therapies targeting these interactions.